Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 8, 2025Open Access

From needles to pills: oral GLP-1 therapy enters the obesity arena

View Full Paper
Ask AI
Bookmark
Share

Authors

GSGaetano SantulliCity College of New York

Discussion

Loading...

Member takes

Implication

Phase-3 trials evaluated oral GLP-1 therapies, showing significant weight loss in adults with obesity, indicating new treatment possibilities.

Key Points

  • Mean weight loss of 11.2% achieved with orforglipron in 3,127 participants, emphasizing therapeutic potential.
  • Oral semaglutide led to a 13.6% weight reduction over 64 weeks in adults, showcasing efficacy and benefits.
  • Both GLP-1 therapies improved metabolic parameters, although gastrointestinal adverse events were observed.
  • Real-world adoption of oral GLP-1 therapies will depend on tolerability, adherence, and insurance coverage.

Cite This Study

Gaetano Santulli (2025) studied this question.

synapsesocial.com/papers/68e6679587ecc93a24d17468https://doi.org/10.1186/s40842-025-00245-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Once-Weekly Semaglutide in Adults with Overweight or Obesity2021 · 5,106 citations